The global burden of obesity requires advanced pharmacological interventions. Recent clinical data highlights the potential of Cagrisema for weight loss, showing superior results compared to semaglutide monotherapy. This systematic review and meta-analysis analyzed data from randomized controlled trials involving over 3,500 individuals. Consequently, researchers identified significant improvements in body mass index and glycemic markers among patients treated with the combination therapy.

Superior Efficacy of Cagrisema for Weight Loss

The meta-analysis revealed that Cagrisema produced a significantly greater percentage change in body weight compared to semaglutide. Specifically, the mean difference was approximately -7.47%, indicating a robust additive effect. Furthermore, the combination group achieved more pronounced absolute weight loss and BMI reductions. Although semaglutide remains a cornerstone of treatment, these findings suggest that dual-agonist therapies might offer a more potent alternative for severe obesity.

Comparing Safety Profiles

While efficacy is paramount, physicians must consider safety for long-term management. Data showed that patients generally tolerated both therapies well. However, cagrilintide monotherapy caused a higher incidence of gastrointestinal side effects when compared to semaglutide. Interestingly, serious adverse events remained comparable across the groups, supporting the safety of incorporating Cagrisema for weight loss into clinical practice.

In conclusion, the combination of cagrilintide and semaglutide represents a significant leap forward in obesity pharmacotherapy. Practitioners should consider these results when designing personalized weight management plans.

Frequently Asked Questions

How does Cagrisema compare to semaglutide for weight reduction?

Cagrisema combines semaglutide with cagrilintide, a long-acting amylin analogue. The meta-analysis found that this combination leads to significantly greater weight loss and better glycemic control than semaglutide alone.

What are the common side effects of cagrilintide?

Cagrilintide monotherapy often causes gastrointestinal issues such as nausea and vomiting. While these are common, serious adverse events are rare and comparable to other GLP-1 receptor agonists.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Ahmed M et al. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab. 2026 Mar 16. doi: 10.1111/dom.70667. PMID: 41834765.


2. Jin T et al. Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis. Journal of Clinical Question. 2025 Oct 23.


3. Healio. CagriSema superior to semaglutide for weight loss, HbA1c reduction at 68 weeks. 2026 Feb 2.